Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC GlobeNewswire December 01, 2025 TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma“), is pleased to announce that national television network CTV News' flagship […]

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference GlobeNewswire December 01, 2025 IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will participate in a fireside chat at the upcoming 37th Annual Piper Sandler Healthcare Conference

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference GlobeNewswire December 01, 2025 Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will

AmpliTech 5G Division Releases New Band 50 Open RAN Radios Proof Of Concept Phase Complete – Production Shipments To Start December 2025 GlobeNewswire December 01, 2025 HAUPPAUGE, N.Y., Dec. 01, 2025 (GLOBE NEWSWIRE) — AmpliTech Group, Inc. (NASDAQ: AMPG), a leading designer, developer, and manufacturer of state-of-the-art signal processing components, low-noise amplifiers (LNAs), and advanced

Targa Resources Corp. to Acquire Permian Basin Gathering & Processing System for $1.25 Billion GlobeNewswire December 01, 2025 $1.25 billion purchase price represents ~6 times 2026 estimated unlevered adjusted free cash flow Underpinned by long-term acreage dedications of ~170,000 acres and attractive fee-based contracts Stable volume profile with significant additional economic drilling opportunities Further enhances

KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar Investment to support the continued evaluation and redevelopment of KALA's product candidates and patent portfolio, and provide working capital and funding for a potential future strategic transaction GlobeNewswire December 01, 2025 ARLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) — KALA BIO,

Akebia Announces Establishment of Rare Kidney Disease Pipeline GlobeNewswire December 01, 2025 Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stimulator, initiated in focal segmental glomerulosclerosis (FSGS) Both

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition GlobeNewswire December 01, 2025 SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage

NioBay Metals Announces Brokered Life Offering and Concurrent Private Placement for Gross Proceeds of Up to C$5 Million GlobeNewswire December 01, 2025 NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTRÉAL, Dec. 01, 2025 (GLOBE NEWSWIRE) — NioBay Metals Inc. (TSX-V: NBY) (“NioBay” or the “Corporation“), is

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) GlobeNewswire December 01, 2025 TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million, inclusive of